Full Archive
Combined quetiapine and radiation therapy approach to treat mesothelioma-initiating cells and increase survival in a mouse model of mesothelioma
bioRxiv 2025 April 14 [Link] Anjelica Cardenas, Evelyn Arambula, Linda Azizi, Tara Lam, Sabrina Sutlief, Kruttika Bhat, Mohammad Saki, Ling He, Frank Pajonk Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare thoracic cancer associated with poor prognosis and low survival rates. In solid cancers, repurposed dopamine receptor antagonists have been shown to have anti-cancer…
Read MoreMesothelial and immune cells interplay in the tumor microenvironment
Trends in Molecular Medicine 2025 April 29 [Link] Rong Sheng, Yujia Yin, Xipeng Wang Abstract Mesothelial cells (MCs) constitute a dynamic mesothelium in which their numerous crucial functions synergistically interact with other cells to maintain serosal integrity and homeostasis. Previous studies have confirmed the crucial role of interactions between MCs and tumor cells in tumorigenesis…
Read MoreA Rare Case of Sarcomatoid-Type Localized Pleural Mesothelioma Derived From Visceral Pleura
Cureus 2025 March 30 [Link] Takayuki Kosaka, Seshiru Nakazawa, Rikuo Ushikubo, Takashi Ibe, Ken Shirabe Abstract A man in his 80s presented with shortness of breath. Chest CT scan showed pleural effusion and a mass in the right lower lobe. He had high inflammatory reaction and was diagnosed as having pulmonary suppuration with empyema. After…
Read MoreBidirectional Mendelian randomization and potential mechanistic insights into the causal relationship between gut microbiota and malignant mesothelioma
Medicine 2025 April 25 [Link] Yinjie Zhou, Huangkai Zhu, Long Zhao, Guofang Zhao, Jiaen Sun Abstract Malignant mesothelioma (MM) is a rare but aggressive cancer originating from mesothelial cells, which presents significant challenges to patients’ physical and psychological well-being. The gut-lung axis underscores the connection between gut microbiota and respiratory diseases, with emerging evidence suggesting…
Read MoreThe Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma
Cancers 2025 April 20 [Link] Berta Mosleh, Katharina Sinn, Anna Cho, Anton Reiner, Ariane Steindl, Christian Lang, Sabine Zöchbauer-Müller, Karin Dieckmann, Joachim Widder, Helmut Prosch, Balazs Dome, Karin Schelch, Clemens Aigner, Thomas Klikovits, Michal Benej, Stefan Watzka, Martin Filipits, Servet Bölükbas, Pavla Sarova, Daniela Gompelmann, Michael Grusch, Mir Alireza Hoda Abstract Background/objectives: Malignant pleural mesothelioma…
Read MoreEfficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study
Medicina 2025 March 31 [Link] Ziya Kalkan, Senar Ebinc, Murat Arcagok, Ahmet Bilici, Ozcan Yildiz, Saadettin Kilickap, Deniz Can Guven, Ali Murat Tatli, Ahmet Taner Sumbul, Nil Molinas Mandel, Akin Ozturk, Murat Bardakci, Serdar Karakaya, Muhammet Ali Kaplan Abstract Background and Objectives: This study aimed to evaluate the effectiveness of immunotherapy compared to chemotherapy across…
Read MoreTumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook
Current Treatment Options in Oncology 2025 May [Link] Giovanni Luca Ceresoli, Letizia Gianoncelli Abstract Pleural mesothelioma is an incurable cancer with unmet diagnostic and therapeutic needs. Due to its pattern of local spread, few patients are candidates for multimodality treatment and thus most patients only receive systemic therapy. Chemotherapy (pemetrexed plus platinum) was standard of…
Read MoreImmunotherapy in mesothelioma – systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORR
Journal of Chemotherapy 2025 April 22 [Link] Marko Skelin, Kaja Matić, Andrea Anić-Matić, Ivan Krečak, Bruna Perkov-Stipičin, Mirko Grubor Abstract Mesothelioma has a poor prognosis, with a 5-year overall survival (OS) rate less than 5%. Immunotherapy has been proven as a promising alternative to platinum-based therapies in first-line treatment. Our systematic literature search included 7…
Read MoreEfficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma
Lung Cancer 2025 May [Link] Ernest Nadal, Paloma Martín-Martorell, Jose Carlos Benítez, Maria Ángeles Sala, Susana Cedrés, Carlos Álvarez, Manuel Dómine, Elia Sais 8, Maria Saigí, Rafael López, Laia Vilà, Bartomeu Massutí, Rosario García-Campelo, Andres Mesas-Ruiz, Amelia Insa, Sílvia Plans-Marín, Sara Hijazo-Pechero, Cristina Muñoz-Pinedo, Jesús Brenes, Mariano Provencio Abstract Objectives: We aimed to evaluate the…
Read MoreCytoplasmic HuR Expression Enhances Chemoresistance in Pleural Mesothelioma Through Increased Expression of CALB2, Promotion of the E2F Pathway, and Suppression of the p53 Pathway
Thoracic Cancer 2025 April [Link] Susumu Kirimura, Morito Kurata, Hironori Ishibashi, Yusuke Taniguchi, Yuko Kinowaki, Keisuke Sugita, Kenichi Okubo Abstract Introduction: Chemotherapy is crucial for treating pleural mesothelioma; however, the outcomes are poor, necessitating an urgent need to study the mechanism of chemotherapy resistance in mesothelioma cells. Human antigen R (HuR), an RNA-binding protein and…
Read More